Antigen-specific immune modulation with liver-targeting nanoparticles fosters immune protective regulatory T cells to delay Type 1 Diabetes

Poster Helmholtz Munich

Authors: Isabelle Serr, Daria Krzikalla, Barbara Metzler, Sabine Fleischer, Carolin Daniel

Summary

Type 1 Diabetes (T1D) is characterized by the loss of immune tolerance to beta-cells in the pancreas, resulting in their immune-mediated destruction. Restoring antigen-specific immune tolerance, thereby circumventing critical side effects of non-specific immunosuppression is a long-awaited goal for the prevention of T1D. We tested peptideconjugated nanoparticles developed by Topas Therapeutics that leverage the tolerogenic capacity of liver sinusoidal endothelial cells (LSECs) to restore antigen-specific immune tolerance in T1D